Christina Yau

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3323167/publications.pdf

Version: 2024-02-01

44	17,095	201674	289244
papers	citations	27	40
		h-index	g-index

44	44	44	25653
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. Lancet Oncology, The, 2022, 23, 149-160.	10.7	148
2	Survivorship after neoadjuvant chemotherapy â€“ Authors' reply. Lancet Oncology, The, 2022, 23, e96.	10.7	0
3	Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies. Cancer Cell, 2022, 40, 609-623.e6.	16.8	92
4	Circulating tumor DNA and magnetic resonance imaging to predict neoadjuvant chemotherapy response and recurrence risk. Npj Breast Cancer, 2021, 7, 32.	5.2	23
5	PRoBE the cloud toolkit: finding the best biomarkers of drug response within a breast cancer clinical trial. JAMIA Open, 2021, 4, ooab038.	2.0	0
6	Assessment of 25-Year Survival of Women With Estrogen Receptorâ€“Positive/ERBB2-Negative Breast Cancer Treated With and Without Tamoxifen Therapy. JAMA Network Open, 2021, 4, e2114904.	5.9	12
7	Integrative modeling identifies genetic ancestry-associated molecular correlates in human cancer. STAR Protocols, 2021, 2, 100483.	1.2	2
8	Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial. Cancer Cell, 2021, 39, 989-998.e5.	16.8	131
9	Breast MRI during Neoadjuvant Chemotherapy: Lack of Background Parenchymal Enhancement Suppression and Inferior Treatment Response. Radiology, 2021, 301, 295-308.	7.3	17
10	Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer. JAMA Oncology, 2021, 7, 1654.	7.1	42
11	Response to Carter et al.. JNCI Cancer Spectrum, 2020, 4, pkaa016.	2.9	0
12	Mechanism of action biomarkers predicting response to AKT inhibition in the I-SPY 2 breast cancer trial. Npj Breast Cancer, 2020, 6, 48.	5.2	21
13	Predicting breast cancer response to neoadjuvant treatment using multi-feature MRI: results from the I-SPY 2 TRIAL. Npj Breast Cancer, 2020, 6, 63.	5.2	30
14	Association of Event-Free and Distant Recurrenceâ€“Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer. JAMA Oncology, 2020, 6, 1355.	7.1	119
15	MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2â€“Positive and/or Hormone Receptorâ€“Negative Breast Cancers in the I-SPY 2 Trial. Journal of Clinical Oncology, 2020, 38, 1059-1069.	1.6	69
16	Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer. JAMA Oncology, 2020, 6, 676.	7.1	419
17	Comprehensive Analysis of Genetic Ancestry and Its Molecular Correlates in Cancer. Cancer Cell, 2020, 37, 639-654.e6.	16.8	151
18	Assessment of Long-term Distant Recurrence-Free Survival Associated With Tamoxifen Therapy in Postmenopausal Patients With Luminal A or Luminal B Breast Cancer. JAMA Oncology, 2019, 5, 1304.	7.1	33

#	Article	IF	Citations
19	Synchronous Detection of Circulating Tumor Cells in Blood and Disseminated Tumor Cells in Bone Marrow Predicts Adverse Outcome in Early Breast Cancer. Clinical Cancer Research, 2019, 25, 5388-5397.	7.0	27
20	An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. Cell, 2018, 173, 400-416.e11.	28.9	2,277
21	Comprehensive Characterization of Cancer Driver Genes and Mutations. Cell, 2018, 173, 371-385.e18.	28.9	1,670
22	Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer. Cell, 2018, 173, 291-304.e6.	28.9	1,718
23	Oncogenic Signaling Pathways in The Cancer Genome Atlas. Cell, 2018, 173, 321-337.e10.	28.9	2,111
24	Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas. Cell Reports, 2018, 23, 194-212.e6.	6.4	245
25	The Immune Landscape of Cancer. Immunity, 2018, 48, 812-830.e14.	14.3	3,706
26	Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas. Cell Reports, 2018, 23, 239-254.e6.	6.4	801
27	Intratumor Heterogeneity of the Estrogen Receptor and the Long-term Risk of Fatal Breast Cancer. Journal of the National Cancer Institute, 2018, 110, 726-733.	6.3	55
28	Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines. Cell Systems, 2018, 6, 271-281.e7.	6.2	605
29	Genomic and Functional Approaches to Understanding Cancer Aneuploidy. Cancer Cell, 2018, 33, 676-689.e3.	16.8	750
30	A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. Cancer Cell, 2018, 33, 690-705.e9.	16.8	478
31	The WISDOM Personalized Breast Cancer Screening Trial: Simulation Study to Assess Potential Bias and Analytic Approaches. JNCI Cancer Spectrum, 2018, 2, pky067.	2.9	25
32	DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial. Npj Breast Cancer, 2017, 3, 31.	5.2	64
33	Tamoxifen therapy benefit for patients with 70-gene signature high and low risk. Breast Cancer Research and Treatment, 2017, 166, 593-601.	2.5	17
34	Co-expression modules identified from published immune signatures reveal five distinct immune subtypes in breast cancer. Breast Cancer Research and Treatment, 2017, 161, 41-50.	2.5	12
35	Features of MRI stromal enhancement with neoadjuvant chemotherapy: a subgroup analysis of the ACRIN 6657/I-SPY TRIAL. Journal of Medical Imaging, 2017, 5, 1.	1.5	4
36	Adaptive Randomization of Veliparibâ€“Carboplatin Treatment in Breast Cancer. New England Journal of Medicine, 2016, 375, 23-34.	27.0	467

#	Article	IF	Citations
37	Adaptive Randomization of Neratinib in Early Breast Cancer. New England Journal of Medicine, 2016, 375, 11-22.	27.0	301
38	PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression. Nature Medicine, 2016, 22, 1321-1329.	30.7	138
39	Treatment and Long-Term Risks for Patients With a Diagnosis of Ductal Carcinoma In Situâ€"Reply. JAMA Oncology, 2016, 2, 395.	7.1	0
40	A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies. Breast Cancer Research and Treatment, 2016, 155, 521-530.	2.5	27
41	The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer. Clinical Cancer Research, 2015, 21, 2911-2915.	7.0	77
42	Rethinking the Standard for Ductal Carcinoma In Situ Treatment. JAMA Oncology, 2015, 1, 881.	7.1	93
43	Gene Co-Expression Modules as Clinically Relevant Hallmarks of Breast Cancer Diversity. PLoS ONE, 2014, 9, e88309.	2.5	94
44	The Prognostic Implications of Macrophages Expressing Proliferating Cell Nuclear Antigen in Breast Cancer Depend on Immune Context. PLoS ONE, 2013, 8, e79114.	2.5	24